Evidence map›Paper›PMID 31735168›Full record

ArticleJournal of ovarian research2019

Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer.

Elizabeth V Connor, Caner Saygin, Chad Braley, Andrew C Wiechert, Sheelarani Karunanithi, Katie Crean-Tate, Fadi W Abdul-Karim, Chad M Michener, Peter G Rose, Justin D Lathia and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ovarian research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Elizabeth V ConnorDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology and Women's Health Institute, Cleveland Clinic, 801 North 29th Street Billings, MT, Cleveland, OH, 59101, USA. Lizvconnor@gmail.com.ORCID http://orcid.org/0000-0003-4445-1877
Caner SayginCancer Impact Area, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Chad BraleyCancer Impact Area, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Andrew C WiechertDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology and Women's Health Institute, Cleveland Clinic, 801 North 29th Street Billings, MT, Cleveland, OH, 59101, USA.
Sheelarani KarunanithiCancer Impact Area, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Katie Crean-TateDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology and Women's Health Institute, Cleveland Clinic, 801 North 29th Street Billings, MT, Cleveland, OH, 59101, USA.
Fadi W Abdul-KarimDepartment of Anatomic Pathology, Cleveland Clinic, Cleveland, OH, USA.
Chad M MichenerDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology and Women's Health Institute, Cleveland Clinic, 801 North 29th Street Billings, MT, Cleveland, OH, 59101, USA.
Peter G RoseDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology and Women's Health Institute, Cleveland Clinic, 801 North 29th Street Billings, MT, Cleveland, OH, 59101, USA.
Justin D LathiaCancer Impact Area, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Ofer ReizesCancer Impact Area, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. Reizeso@ccf.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOvarian cancer is the leading cause of gynecologic cancer death in the United States despite effective first-line systemic chemotherapy. Cancer stem cells (CSCs) retain the ability to self-renew and proliferate and may be a means of harboring disease that evades standard treatment strategies. We previously performed a high-throughput screen to assess differential protein expression in ovarian CSCs compared to non-CSCs and observed that Thy-1 was more highly expressed in CSCs. Our primary aim was to validate Thy-1 (CD90) as a cancer stem cell (CSC) marker in epithelial ovarian cancer (EOC), correlate with clinical outcomes, and assess as a potential therapeutic target.

resultsKaplan Meier (KM) Plotter data were correlated with survival outcomes. Quantitative real-time PCR, flow cytometry, and immunoblots assessed RNA and protein expression. Limiting dilution assays assessed self-renewal capacity and proliferation assays assessed proliferative capacity. RNA in-situ hybridization was performed on patient specimens to assess feasibility. Thy-1 (CD90) is more highly expressed in ovarian CSCs than non-CSCs, in EOC compared to benign ovarian epithelium (P < 0.001), and is highest in serous EOC (P < 0.05). Serous ovarian cancers with high Thy-1 expression have poorer outcomes (median PFS 15.8 vs. 18.3 months, P = 0 < 0.001; median OS 40.1 v. 45.8 months, P = 0.036). Endometrioid ovarian cancers with high Thy-1 have poorer PFS, but no difference in OS (upper quartile PFS 34 v. 11 months, P = 0.013; quartile OS not reached, P = 0.69). In vitro, Thy-1 expression is higher in CSCs versus non-CSCs. EOC cells with high Thy-1 expression demonstrate increased proliferation and self-renewal. Thy-1 knockdown in EOC cells decreases proliferative capacity and self-renewal capacity, and knockdown is associated with decreased expression of stem cell transcription factors NANOG and SOX2. RNA in situ hybridization is feasible in ovarian cancer tissue specimens.

conclusionsThy-1 is a marker of ovarian CSCs. Increased expression of Thy-1 in EOC predicts poor prognosis and is associated with increased proliferative and self-renewal capacity. Thy-1 knockdown decreases proliferative and self-renewal capacity, and represents a potential therapeutic target.

Indexed as

AgedAged, 80 and overBiomarkers, TumorCell Line, TumorCell Self RenewalChemoradiotherapy, AdjuvantFemaleHumansKaplan-Meier EstimateMiddle AgedNeoplastic Stem CellsOvarian NeoplasmsPrognosisThy-1 AntigensTreatment OutcomeBiomarkers, TumorThy-1 AntigensBiomarkerCancer stem cellsCD90Ovarian cancerSelf-renewalThy-1

Identifiers

PMID31735168
PMCPMC6858973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.